Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Accumulated Expenses (2016 - 2025)

Dexcom (DXCM) has disclosed Accumulated Expenses for 14 consecutive years, with $116.1 million as the latest value for Q2 2024.

  • On a quarterly basis, Accumulated Expenses changed N/A to $116.1 million in Q2 2024 year-over-year; TTM through Jun 2024 was $116.1 million, a N/A change, with the full-year FY2022 number at $134.3 million, up 7.27% from a year prior.
  • Accumulated Expenses was $116.1 million for Q2 2024 at Dexcom, down from $134.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $134.3 million in Q4 2022 to a low of $59.0 million in Q1 2020.
  • A 4-year average of $101.4 million and a median of $112.7 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: fell 8.8% in 2020, then soared 45.55% in 2021.
  • Dexcom's Accumulated Expenses stood at $114.3 million in 2020, then grew by 9.54% to $125.2 million in 2021, then grew by 7.27% to $134.3 million in 2022, then fell by 13.55% to $116.1 million in 2024.
  • Per Business Quant, the three most recent readings for DXCM's Accumulated Expenses are $116.1 million (Q2 2024), $134.3 million (Q4 2022), and $112.7 million (Q3 2022).